GLP-1 Starting Dose OPTIMIZER
by Dr Richard Lipman, M.D.
Board Certified Internal Medicine/Endocrinology
GLP-1 Starting Dose OPTIMIZER recognizes that everyone reacts differently to GLP-1’s, and there are simple techniques to individualize treatment dosing that can improve comfort, reduce side effects, increase long-term adherence, and help patients achieve weight-loss success. This all starts out with determining the optimal preparation and STARTING dose
Choosing the “Right”: Starting Dose
Many physicians now recommend initiating Zepbound, Wegovy, and other GLP-1 medications at individualized starting doses. Experienced obesity specialists have been adjusting the starting dose for their new patients for several years, taking into account factors such as age, prior GLP-1 use, digestive health, medication sensitivity, current medications, and other medical conditions. Figure 1 lists the tirzepatide doses supplied by the manufacturer. Note that 2.5 mg is a “test dose.”
Figure 1: Dosing of Zepbound and Mounjaro
For example, with so many patients having previously tried GLP-1 medications, starting doses often need to be adjusted UPWARD based on their prior experience. Patients who have experienced gastrointestinal reactions in previous trials or have a strong history of recurrent gastrointestinal disease might benefit from starting at a dose –DOWNWARD below the usual initiating dose. This personalized approach has proven to improve medication tolerance and reduce side effects such as nausea and gastric pain. This has helped patients remain on treatment long enough to achieve meaningful weight loss.
FDA Permits Dosing Adjustments
*FDA-approved labeling specifies standard initiation schedules, but clinicians may individualize treatment when appropriate based on the patient’s medical history and tolerance.
Lipman Personalized GLP-1 Starting Dose Algorithm™
A Personalized Approach Based on Age, Frailty, Previous GLP-1 Use, Gastrointestinal History, and Medication Sensitivity
Richard Lipman, MD • Version 1.0 • July 2026
How to Use the Algorithm
- Review previous GLP-1 use
Record the prior agent and route, highest dose reached, last dose and date, time off treatment, clinical response, and tolerance—especially nausea, vomiting, reflux/heartburn, or other gastrointestinal intolerance. If the patient is currently taking and tolerating the same medication without interruption, the new-start table may not apply. For a restart or product switch, use product-specific prescribing information where available and reassess current tolerance rather than automatically resuming the former maintenance dose.
- Choose one reduction column
Match the patient to the most conservative applicable column. A 25% reduction means the patient receives 75% of the standard starting dose; a 75% reduction means the patient receives only 25% of the standard starting dose. When risk factors fall in more than one column, use the greater reduction.
- Screen gastrointestinal and medication-sensitivity risk
Give particular weight to older age, frailty, lower body weight, medication sensitivity, prior GLP-1 intolerance, GERD/reflux/chronic heartburn, hiatal hernia, severe prior nausea or vomiting, significant GI sensitivity, and multiple medical conditions. Review current anti-reflux therapy and consider clinician-directed initiation of a proton pump inhibitor or H2-receptor blocker when clinically appropriate; supportive therapy does not replace dose reduction or follow-up.
- Reassess before escalation
Escalate only after adequate tolerance. Delay escalation or reduce the plan when clinically significant GI symptoms, poor oral intake, risk of dehydration, or other safety concerns are present. Do not combine GLP-1 receptor agonists; use the current full prescribing data.
Clinical Footnotes & Publication Notes:
Read with the table and the current U.S. prescribing information.
1 | Labeled starting doses. The 0% column reflects labeled U.S. initiation doses current in July 2026: tirzepatide injection 2.5 mg once weekly; semaglutide injection 0.25 mg once weekly; Wegovy tablets 1.5 mg once daily; and Foundayo 0.8 mg once daily. |
2 | Lipman reduction categories. The 25%, 50%, and 75% columns are individualized clinical categories and are not FDA-approved starting-dose schedules. Tirzepatide values are exact arithmetic reductions. Semaglutide values are rounded from 0.1875 mg and 0.0625 mg to 0.188 mg and 0.063 mg. |
† | Fractional injections. Reduced injection amounts may not correspond to a labeled strength or a dose deliverable by a branded single-dose pen. Do not alter, transfer, or extract medication from a single-dose device. When a legally supplied multidose or compounded preparation is used, independently verify the source, concentration, prescribed milligrams, injection volume, measuring device, and sterility instructions. |
* | Reduced oral schedules. Every-other-day, 3-days-per-week, and 2-days-per-week schedules are off-label, clinician-supervised tolerability tiers; they are not mathematically equivalent to the percentages in the column headings. Wegovy and Foundayo labeling specifies once-daily administration. Swallow tablets whole; do not split, crush, chew, or dissolve them. The goal of a reduced schedule is improved early tolerability followed by transition toward labeled daily dosing when appropriate. |
3 | Previous GLP-1 exposure. Before initiation, reinitiation, or switching, document the prior drug, route, highest tolerated dose, last dose and date, time off treatment, response, and adverse effects. Use label-specific restart or switching directions when available. A prior maintenance dose should not automatically be resumed after an interruption if tolerance may have changed. |
4 | GI history and supportive therapy. GERD, reflux, chronic heartburn, hiatal hernia, significant GI sensitivity, or severe prior nausea/vomiting may justify a lower starting tier and closer follow-up. Review current acid-suppressive therapy and consider a proton pump inhibitor or H2-receptor blocker only when clinically indicated; this is not an automatic requirement and does not replace dose adjustment. |
5 | Scope and safety. This clinician reference does not reproduce all contraindications, boxed warnings, drug interactions, monitoring requirements, or missed-dose instructions. Do not use GLP-1 receptor agonists concurrently. Escalate only after adequate tolerance and use the current full prescribing information and independent clinical judgment for every patient. |